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ABSTRACT
Molecular remission (MR) is associated with improved outcome in mantle cell lymphoma (MCL). If MR is not
achieved, patients are at high risk of relapse. We retrospectively describe the molecular and clinical follow-ups
of 4 patients with molecular relapses (M-rels) who were treated with rituximab. The 4 patients received
rituximab-supplemented, high-dose sequential chemotherapy and autologous stem cell transplantation as
induction treatment and achieved clinical remission and MR. M-rel was defined as polymerase chain reaction
(PCR) positivity in 2 consecutive samples in the absence of clinical relapse. M-rels occurred at 3, 6, 39, and 52
months and were always confirmed by direct sequencing of the clonal rearrangement. Minimal residual disease
was monitored by qualitative and real-time quantitative PCR. All patients received 4 courses of rituximab, with
2 additional infusions if PCR positivity remained. After 4-6 courses of rituximab, all patients re-entered MR.
No clinical relapses were recorded at 3, 6, 18, and 62 months from treatment, although 1 patient had a second
M-rel that was sensitive to rituximab. Our results indicate that rituximab is active against residual MCL cells
and suggest that molecularly tailored maintenance therapy needs to be investigated in clinical trials.
© 2006 American Society for Blood and Marrow Transplantation
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Mantle cell lymphoma (MCL) is 1 of the worst
ubtypes of B cell lymphoma, with a median overall
urvival that does not exceed 4 years with conventional
hemotherapy [1]. Aggressive treatment with autolo-
ous stem cell transplantation (ASCT) in the era before
ituximab was attempted to improve outcome [2-4]. Al-
hough some good results were reported, ASCT was not
urative as documented by the nearly constant persis-
ence of molecularly detectable disease [1-5]. Rituximab
as been employed in MCL as in most CD20-positive
eoplasms [6,7]. However, the value of this drug is not
xhaustively established. It is an effective single-agent
rug that induces short-term responses in approximately r
2705% of rituximab-naive relapsed/refractory patients at
iagnosis or at relapse [8,9]. When combined with con-
entional chemotherapy, rituximab is also beneﬁcial.
he German Low-Grade Lymphoma Study Group has
bserved a better response rate and time to treatment
ailure in rituximab-treated patients. However, this was
ot associated with an improved progression-free sur-
ival and overall survival [10]. The combination of rit-
ximab and ASCT has been attempted in phase II trials,
ith excellent results [11,12], although randomized stud-
es are lacking. One important observation was the fre-
uent achievement of molecular remission (MR). This
as rarely observed in patients with MCL treated with
ituximab-free autografting regimens [2,4].
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Treatment of Molecular Relapse in MCL 1271MR, particularly when associated with a clinical
emission (CR), is a sign of major cytoreduction, al-
hough it does not indicate disease eradication. Nev-
rtheless, a recent report by Pott et al [13] has dem-
nstrated that the achievement of MR is a major
avorable prognostic indicator in MCL. Although many
atients with MCL achieve MR with rituximab-supple-
ented ASCT programs, molecular relapse (M-rel) is
requently observed and represents an early warning for
ubsequent clinical relapse. We retrospectively describe
he clinical and molecular results of 4 patients who de-
eloped M-rel after a documented molecular response
chieved with a rituximab-supplemented, high-dose se-
uential chemotherapy (R-HDS) program. Patients
ere analyzed with qualitative and real-time quantitative
olymerase chain reaction (PCR).
ETHODS
atients’ Clinical Features and Treatment
odality
Four patients were treated with R-HDS outside
he context of a clinical trial (Table 1): 3 patients were
ever enrolled in a clinical trial and the fourth partic-
pated in a small preliminary study whose endpoints
ere exclusively feasibility, toxicity, and early molec-
lar outcome. At the time of M-rel, their treating
hysicians decided that rituximab retreatment was an
ppropriate choice from a clinical viewpoint based on
everal published and personal unpublished observa-
ions suggesting that M-rel is rapidly followed by
linical relapse in MCL [4,13] (Ladetto, unpublished
bservation; Magni, unpublished observation). The
-HDS regimen has been reported elsewhere [11,12].
rieﬂy, patients were initially treated with 2 to 3
ourses of doxorubicin (75 mg/m2 of body surface area
iven intravenously on day 1), prednisone (40 mg/m2
rally given from days 1 to 21), and vincristine (1.4
g/m2 given intravenously on day 1). After the initial
able 1. Main Clinical Features
Patient
Identification Age Sex Stage aaIPI
BM
Involvement
Mol
Ma
CL-77 42 M IVA 1 10% t(1
CL-81 63 M IVB 2 10% t(1
CL-57 56 M IVB 2 40% IgH
CL-51 57 M IVA 1 1% IgH
aIPI indicates age-adjusted international prognostic index; BM
supplemented, high-dose sequential chemotherapy; M-rel, molec
CR, complete remission.
Follow-up from the end of R-HDS to ﬁrst M-rel.
Follow-up from the end of R-HDS to second M-rel.
Follow-up from ﬁrst post-rituximab PCR-negative result after the
Follow-up from ﬁrst post-rituximab PCR-negative result after the secontandard dose phase, all patients received the 4-step
igh-dose sequence, including intravenous adminis-
ration of high-dose cyclophosphamide (7 g/m2),
igh-dose cytarabine (1.5 or 2 g/m2 every 12 hours for
consecutive days), high-dose melphalan (180 mg/
2), and high-dose mitoxantrone plus melphalan (60
nd 180 mg/m2, respectively). Stem cell collections
ere taken after high-dose cyclophosphamide and high-
ose cytarabine. Minimum delay between courses was 3
eeks but delays were considered depending on hema-
ologic and nonhematologic toxicities. It should be
ointed out that this program includes 6 rituximab in-
usions at the dosage of 375 mg/m2. Two doses were
iven after high-dose cyclophosphamide the day after
hemotherapy and the day before stem cell collection.
wo doses were given after high-dose cytarabine with
similar schedule. The last 2 doses were given at the
nd of the entire program. To hasten hematopoietic
ecovery, each patient received 3 progenitor/stem cell
einfusions after the nonmyeloablative course of high-
ose cytarabine and after the 2 subsequent myeloab-
ative courses of melphalan and mitoxantrone plus
elphalan. The minimum target doses of CD34
ells/kg of body weight to be reinfused after each of
he 3 autografts were 2, 3, and 5  106, respectively.
CR-negative stem cell collections were always pre-
erred for autografting procedures. Complete CR was
eﬁned according to the criteria of Cheson et al [14].
ollow-up evaluations including physical examination,
omputed tomographic scan, bone marrow biopsy,
ell blood counts, and blood chemistry were per-
ormed at 3, 6, and 12 months during the ﬁrst year, at
east twice in the second and third years after trans-
lantation, and then at least yearly. M-rel was deﬁned
s reappearance of PCR positivity in 2 subsequent
one marrow samples taken with an interval of 30
ays. Three patients were treated at the University of
orino and 1 at the Istituto Tumori of Milan. Risk and
dvantages of the planned treatment were carefully dis-
Follow-up
Reinduction
of MR/Final
Follow-up
Visit
Clinical Status
at Final
Follow-up
Visit
PCR Status at
End of R-HDS
End of
R-HDS/M-rel
Negative 3 16 CR
Negative 42 12 CR
Negative 6* 58‡ CR
36† 24§
Negative 55 11 CR
marrow; PCR, polymerase chain reaction; R-HDS, rituximab-
lapse; MR, molecular remission; M, male; IgH, immunoglobulin H;
-rel to ﬁnal clinical observation.ecular
rker
1;14)
1;14)
, bone
ular re
ﬁrst M
d M-rel to ﬁnal clinical observation.
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M. Ladetto et al.1272ussed with the patients and informed consent was
igned by all. Four weekly doses of rituximab were de-
ivered at the dosage of 375 mg/m2. In case of persistent
CR positivity, 2 additional infusions were delivered.
CR Amplification of t(11;14) Translocation by
ualitative and Quantitative PCR
Qualitative PCR ampliﬁcation of the t(11;14)
ranslocation was performed by using a seminested
CR approach as described by Andersen et al [2].
eaction conditions for the ﬁrst and second rounds of
mpliﬁcation were a ﬁrst cycle at 94°C for 3 minutes,
ollowed by 30 cycles with denaturation at 94°C for 30
econds, annealing at 55°C for 30 seconds, and exten-
ion at 72°C for 30 seconds, with a ﬁnal extension time
f 10 minutes. PCR products were then run in 2%
garose gels containing ethidium bromide and visual-
zed under UV light. Each reaction was performed
sing appropriate negative and positive controls. The
ature of the rearrangements was conﬁrmed by direct
equencing. Real-time quantitative PCR was per-
ormed with an adapted version of the method de-
cribed by Olsson et al [15] and the same primers and
aqMan probes. Real-time PCR conditions have been
escribed; brieﬂy, 400 ng of target DNA was ampli-
ed in 50 L using the TaqMan PCR MasterMix
PE Applied Biosystems, Foster City, Calif). Reactions
ere performed in an AbiPrism 7900 sequence detec-
or system (PE Applied Biosystems) under the follow-
ng conditions: after an incubation of 2 minutes at
0°C and an incubation of 10 minutes at 95°C, the
ollowing reaction was run: 42 cycles of denaturation
t 95°C for 15 seconds and annealing at 60-62°C for 1
inute. Absolute quantiﬁcation of the number of re-
rrangements was done using serial 10-fold dilutions
f plasmid containing the cloned rearrangement,
tarting from 106 plasmid copies, as described else-
here [16]. Quantitation standards were obtained by
loning the tumor-speciﬁc t(11;14) rearrangement us-
ng the TA Cloning Kit as published elsewhere [16].
ormalization of samples for DNA quality and quan-
ity was done using the glyceraldehyde 3-phosphate
ene, as previously described [17].
When a sample was scored to be PCR positive by
ested PCR and PCR-negative by real-time PCR, the
core was deﬁned as “below the sensitivity threshold”
f real-time PCR (BST). Triplicate analyses of real-
ime PCR can detect a single clonal rearrangement in
ach tube. Thus, based on the amount of DNA tested,
he sensitivity of real-time PCR is 5 clonal rearrange-
ents (cr)/106. This leads to a postulate that the
lonal burden of a BST sample might range from
cr/106 cells (sensitivity threshold of real-time PCR)
o 1.0 cr/106 cells (sensitivity threshold of nested
CR). Thus, for the purpose of this analysis, the
lonal cell burden of BST samples was placed equal to che mean of the 2 values, ie, 3 Bcl-1/immunoglobulin
eavy chain gene (IgH) cr /106 dg.
mplification, Sequencing, Qualitative, and
eal-Time Quantitative PCR for the IgH
earrangement
Patient-speciﬁc IgH rearrangements were ampli-
ed and direct-sequenced from tumor-derived genomic
NA (ie, bone marrow or lymph node) obtained at
iagnosis. For these reactions, consensus sense primers
erived from the leader (L) and ﬁrst framework region
FR1) and a consensus antisense primer derived from
he FR4 were employed as previously described [16].
ased on the IgH sequence, tumor-speciﬁc primers
erived from the second and third complementarity-
etermining region (CDR) were designed and synthe-
ized to perform qualitative minimal residual disease
MRD) evaluation by nested ampliﬁcation, as described
lsewhere [18]. Real-time quantiﬁcation of the number
f IgH rearrangements was performed on genomic
NA samples using tumor-speciﬁc primers and consen-
us probes, as previously reported [16]. The sense primer
as derived from the CDR2 or FR3, and the antisense
rimer was always generated from the highly hypervari-
ble CDR3, as previously reported [16]. Consensus
robes for real-time PCR analysis were derived from the
R3 as previously reported. Sequences of these probes
ave been already detailed elsewhere [16].
Absolute quantiﬁcation was performed by cloning
he patient-speciﬁc IgH rearrangement and by pre-
aring six 10-fold dilutions of cloned rearrangements
s previously described [16]. DNA normalization and
uantiﬁcation of samples scoring PCR positive by
ested PCR and PCR negative by real-time PCR were
one as for the t(11;14).
ESULTS
linical Results
All patients were in CR and maintained their status
hroughout the entire observation period. All patients
ad normal complete blood cell counts and routine
hemistry values. As planned in the R-HDS, these pa-
ients were kept on acyclovir and cotrimoxazole prophy-
axis for the ﬁrst year after transplantation. Rituximab
nfusion produced no side effects in any patient.
olecular Follow-up by Nested PCR
The 4 patients were monitored for 76, 71, 58 and
8 months from transplantation. All 4 patients re-
eived PCR-negative grafts after the 2 submyeloabla-
ive procedures. Their molecular follow-up by nested
CR is shown in Figure 1. Overall, 42 MRD deter-
inations were done by nested PCR on post-trans-
lantation bone marrow samples. Two M-rels oc-
urred early after transplantation at 3 and 6 months,
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Treatment of Molecular Relapse in MCL 1273espectively. Two subsequent M-rels occurred at 39
nd 52 months from the end of treatment. All M-rels
ere conﬁrmed to be related to the original tumor
lone by direct sequencing of the t(11;14) transloca-
ion or IgH rearrangement.
All 4 M-rels responded to rituximab treatment as
emonstrated by a reversion to MR in the 4 patients
fter 4 or 6 rituximab courses (Figure 1). This status
as been maintained in 3 patients at 5, 6, and 18
onths, whereas patients MCL-57 developed a sec-
nd M-rel 24 months later. Of note, the second re-
apse was responsive to rituximab and PCR negativity
igure 1. Molecular monitoring of patients with MCL and time
lsewhere [11]. Rituximab was delivered at the dosage of 375 mg/m
igure 2. Quantitative monitoring of MRD at M-rel and after ritu
is second M-rel, this patient received only 4 rituximab courses, 2 before theas achieved and has been maintained at 24 months
rom the ﬁnal rituximab infusion. From a clinical
iewpoint at the ﬁnal follow-up visit, patients showed
o sign of active lymphoma at 11, 12, 16, and 24
onths from reinduction of M-rel (when considering
second reinduction for patient MCL-57).
olecular Follow-up by Quantitative
eal-Time PCR
Figure 2 shows the results of quantitative moni-
oring of clonal cells at the time of M-rel and after
of rituximab delivery. The R-HDS program has been described
treatment. Both M-rels of patient MCL-57 were studied. *Duringpointsximab
ﬁrst post-treatment time point and 2 before the second time point.
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M. Ladetto et al.1274ituximab treatment. For patient MCL-57, both M-
els were studied.
Real-time PCR indicated that, from the ﬁrst PCR-
ositive result to the conﬁrmatory assessment, tumor
urden was stable or increasing. Interestingly, at the
ime of his ﬁrst M-rel, patient MCL-57 was not
reated immediately but only after 5 months. This was
ssociated with a more pronounced increase in tumor
ell burden compared with the other patients. This
ncrease clearly indicated the presence of active dis-
ase. Rituximab treatment always induced a reduction
f residual tumor cell burden that resulted in PCR
egativity after 4 courses in 2 cases and after 6 courses
n 3.
ISCUSSION
This retrospective report indicates, for the ﬁrst
ime, that rituximab can reinduce MR in patients with
CL who develop M-rel after intensiﬁed rituximab-
ontaining autografting regimens. None of the pa-
ients re-entering MR developed clinical relapse. MR
s reinduced for periods that are non-negligible, al-
hough it is probably not permanent. One patient with
long follow-up had a second M-rel that was again
ensitive to rituximab.
Persistence of molecular disease is a major nega-
ive prognostic feature in several B cell lymphomas.
lthough this observation was initially established in
ollicular lymphoma [19], several studies have shown
hat the same is true for MCL. In the age before
ituximab, Andersen et al [2] and Corradini et al [4]
howed that patients with MCL remain PCR positive
n the vast majority of cases and develop early clinical
elapse [2,4]. In contrast, allogeneic transplant recip-
ents are often characterized by persistent MR [2,20].
fter the introduction of regimens such as R-HDS,
hich combine rituximab and high-dose sequential
hemotherapy with ASCT, a signiﬁcant increase in
he rate of MR was observed [11,12]. The clinical
alue of R-HDS is difﬁcult to deﬁne because it has not
een assessed in randomized trials. However, these
CR-negative patients had an outcome that compared
avorably to the typical outcome of MCL. Recent
ork from Pott et al [13] has clearly shown that
chievement of MR ensures a signiﬁcantly better
ong-term outcome in patients with MCL.
The clinical decision of delivering rituximab in the
resence of a documented M-rel without additional
igns of disease activity was made after taking into
ccount the good toxicity proﬁle of rituximab and the
ncreased risk of relapse typical in patients with this
ondition. These considerations were further sup-
orted by the sharp increase in tumor burden ob-
erved between the ﬁrst and second molecular assess-
ents by real-time quantitative PCR. bOur study shows that, in case of M-rel, rituximab
llows reinduction of a PCR-negative status. This
ccurs even if patients have already received several
ourses of rituximab, suggesting that residual tumor
ells are still sensitive to this agent. Because our series
f patients is small, we cannot demonstrate that PCR
egativity restores the low-risk status associated with
R. However, it is worth mentioning that none of
ur patients has so far relapsed at 11, 12, 16, and 24
onths from reinduction of M-rel (considering sec-
nd reinduction for patient MCL-57). Undoubtedly a
arger experience and a longer follow-up will help
larifying this issue.
Rituximab has been commonly employed as main-
enance treatment in lymphoid malignancies [21-23].
he beneﬁt of this treatment has been clearly dem-
nstrated in several phase III trials for patients with
ollicular lymphoma [22,23]. In MCL, the use of rit-
ximab in the context of a “prolonged treatment”
chedule has been investigated by Ghielmini et al [24].
his study has clearly shown that prolonged delivery
f rituximab as a single agent is not able to improve
he outcome of patients with MCL [24]. However,
atients included in this study were not in a phase of
xtensive cytoreduction. This indicates that rituximab
lone is probably not able to control disease in the
resence of large amounts of tumor cells. This might
rovide an additional rationale for the use of mainte-
ance rituximab in a MRD setting in MCL. Our data
uggest that a customized delivery, based on molecular
esults, might be an alternative strategy worthwhile of
nvestigation in clinical trials to improve clinical efﬁ-
acy and ensure rational and cost-effective use of ex-
ensive drugs.
Molecular monitoring of MRD, particularly by real-
ime PCR, has gained considerable success in several
ematologic cancers, in particular chronic myelogenous
eukemia [25] and acute promyelocytic leukemia [26].
ts use in mature lymphoproliferative disorders is less
stablished. We have shown that real-time PCR using
he t(11;14) or IgH rearrangement allows accurate
isease monitoring. In 2 cases, the clonal cell burden
ppeared to be increasing before rituximab delivery,
hus providing good kinetic evidence of the presence
f active disease. In addition, rituximab effectively
nduced a progressive disease reduction that was ef-
ectively monitored by real-time PCR. Interestingly,
ome patients reverted to PCR negativity after 4
ourses, whereas others required 6 courses. Of note,
he patient with the greatest tumor load had a prompt
esponse after only 4 cycles of rituximab. This sug-
ests the existence of different levels of sensitivity to
ituximab, although the numbers are too small to draw
eﬁnite conclusions.
This study is only 1 of several reports that indicate
hat molecular monitoring of MRD is becoming ro-
ust enough for widespread use in mature lymphopro-
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Treatment of Molecular Relapse in MCL 1275iferative disorders. Obviously, many well-designed
rospective clinical trials need to be performed in
uture years to build a strong basis for the use of MRD
s a routine clinical tool in non-Hodgkin lymphoma.
everal of these studies employing PCR results as
ajor endpoints of clinical activity and for treatment
ailoring are ongoing at our institution and worldwide
n lymphoma and multiple myeloma. As far as MCL is
oncerned, a prospective trial assessing the value of
olecularly tailored treatment is under discussion in
he context of our cooperative group.
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